{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:59:33Z","timestamp":1780981173777,"version":"3.54.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bispecific antibodies have expanded treatment options for relapsed or refractory multiple myeloma, but treatment initiation remains operationally challenging because product-specific step-up dosing concentrates the highest risk of early immune-mediated toxicity. This structured narrative review synthesizes current prescribing information, clinical safety reports, expert guidance, implementation literature, and nursing-relevant supportive-care evidence for ambulatory step-up dosing. We revised the framework to move beyond a label-based summary and conceptualize outpatient initiation as a biologically informed, resource-stratified, and failure-aware model. Approved agents differ in target antigen, route of administration, step-up schedule, premedication, cytokine release syndrome (CRS) timing, monitoring requirements, and long-term toxicity patterns; these differences should translate into different observation windows, home-surveillance instructions, and escalation thresholds. Patient selection should integrate clinical stability, disease burden, immune reserve, baseline neurologic status, caregiver reliability, geography, communication capacity, and institutional rescue capability. The bone marrow microenvironment, T-cell fitness, tumor adaptation, antigen heterogeneity, and cumulative immune injury from prior therapies may influence both response and toxicity, supporting a translational approach to outpatient risk assessment. We propose practical decision matrices for product-specific monitoring, candidate assessment, CRS-infection dual-track fever evaluation, neurotoxicity detection, failure-mode mitigation, and continuous program evaluation. Outpatient step-up dosing should therefore be considered a selective high-acuity care model rather than a routine efficiency strategy. Prospective validation of eligibility criteria, remote monitoring, nursing-sensitive outcomes, and resource-stratified pathways is urgently needed.<\/jats:p>","DOI":"10.3389\/fonc.2026.1859755","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:32:02Z","timestamp":1780979522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanfeng","family":"Song","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","article-title":"Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study","volume":"64","author":"Wang","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","article-title":"TECVAYLI (teclistamab-cqyv) injection, for subcutaneous use [prescribing information","volume-title":"U.S. Food and drug administration.","year":"2026"},{"key":"B8","article-title":"ELREXFIO (elranatamab-bcmm) injection, for subcutaneous use [prescribing information","volume-title":"DailyMed","year":"2026"},{"key":"B9","article-title":"TALVEY (talquetamab-tgvs) injection, for subcutaneous use [prescribing information","volume-title":"DailyMed.","year":"2025"},{"key":"B10","article-title":"LYNOZYFIC (linvoseltamab-gcpt) injection, for intravenous use [prescribing information","volume-title":"DailyMed.","year":"2025"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00489","article-title":"Real-world safety and health care resource utilization of teclistamab under an outpatient model for step-up dosing administration","volume":"21","author":"Sandahl","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: an analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Info Libr J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA - a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.12.015","article-title":"Bispecific antibody therapy for multiple myeloma: a practical toolkit","volume":"26","author":"Rodriguez","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70176","article-title":"Outpatient delivery of step-up doses to rapidly initiate monthly doses of bispecific antibodies in multiple myeloma","author":"Ramirez-Alvarado","year":"2026","journal-title":"Eur J Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses","volume":"26","author":"Lee","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1188\/18.CJON.421-428","article-title":"Patient handoff processes: implementation and effects of bedside handoffs, the teach-back method, and discharge bundles on an inpatient oncology unit","volume":"22","author":"Callaway","year":"2018","journal-title":"Clin J Oncol Nurs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma","volume":"19","author":"Pan","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288187","article-title":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","volume":"111","author":"Cani","year":"2026","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1188\/19.CJON.288-294","article-title":"Teach-back method: using a nursing education intervention to improve discharge instructions on an adult oncology unit","volume":"23","author":"Scott","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231350","article-title":"Teach-back: a systematic review of implementation and impacts","volume":"15","author":"Talevski","year":"2020","journal-title":"PLoS One"},{"key":"B35","article-title":"AHRQ Health Literacy Universal Precautions Toolkit, Second Edition","author":"Brega","year":"2015"},{"key":"B36","article-title":"Health at a glance: asia\/pacific 2022: measuring progress towards universal health coverage","volume-title":"OECD publishing.","year":"2022"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03991-5","article-title":"Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed\/refractory MM","volume":"122","author":"Iida","year":"2025","journal-title":"Int J Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287334","article-title":"Talquetamab, a GPRC5D x CD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study","volume":"111","author":"An","year":"2026","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: a journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Adm Policy Ment Health"},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13012-023-01286-z","article-title":"Ten years of implementation outcomes research: a scoping review","volume":"18","author":"Proctor","year":"2023","journal-title":"Implement Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859755\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:32:33Z","timestamp":1780979553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859755\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1859755"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1859755","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1859755"}}